Aggressive Angiomyxoma, Angiomyofibroblastoma, and Cellular Angiofibroma of the Lower Female Genital Tract: Related Entities With Different Outcomes

Saroona Haroon 1,2, Lalaih Irshad 1, Shamail Zia 3, Abrahim H. Ali 4, Tanim Ud Dowlah 5, Khushbakht Rashid 6, Umair Arshad Malik 7, Anam N. Khan 8, Muhammad Irfan 9, Atif A. Hashmi 10

Abstract
Introduction
Mesenchymal tumors of the lower female genital tract (FGT) are a miscellaneous group of tumors that include aggressive angiomyxoma (AAM), angiomyofibroblastoma (AMFB), cellular angiofibroma (CAF), and related entities. Histologically, these tumors are composed of stromal cells admixed with vessels, with some minor histological differences. An accurate diagnosis of these tumors is important owing to the differences in the outcome. In this study, we determined the clinicopathological characteristics of these tumors in our population and their association with recurrence.

Methods
This was a retrospective cross-sectional study conducted at the Department of Histopathology, Aga Khan University, from January 2005 to December 2019 over a period of 15 years. A total of 207 cases that were diagnosed as AAM, AMF, and CAF were selected for inclusion in the study. Clinical data, including age and location of the lesion, were obtained from histopathology referral forms. Tissue blocks of all cases were retrieved. Follow-up data were obtained from the patient files, and information regarding disease recurrence was recorded. One histological section from each tissue block was stained with hematoxylin and eosin stain, and immunohistochemical (IHC) studies, including vimentin, smooth muscle actin (SMA), and desmin were conducted on representative tissue blocks. Final histopathological diagnoses were rendered considering clinical, histopathological, and IHC findings.

Results
The median age of patients involved in the study was 33 years and the median tumor size was 5 cm with a predilection for the vulva (47.3%). AAM showed a predilection for patients between the ages of 31–45 years, while AMFBs and CAFs were most common in younger age groups of less than 30 years. In 46.8% of cases, the tumor size of AAM was between 6 and 10 cm, while in all cases of CAF (100%) and the majority of AMFB cases (53.2%) the tumor size was smaller than 5 cm. Histologically, in all cases of AAM, the lesional cells were spindle (100%), whereas, in 15% of cases epitheloid cells were observed, with myxoid stroma in 92.2% cases. The presence of stromal smooth muscle was noted in 42.9% of cases, in 79.2% of cases the vessels were thick-walled, with 54.5% having hyalinized vessels, and most of the cases (77.9%) had ill-defined borders. Among IHC findings, AMFB was most frequently positive for actin (62.2%), while AAM and AMFB showed more frequent staining for desmin compared to CAF. A significantly higher recurrence rate was observed in AAM (27.5%), compared to AMFB and CAF. A significant association of recurrence was seen with tumor size. It was noted that the recurrence rate was directly proportional to the size of the tumor and was highest (60%) with a tumor size of more than 10 cm.

Conclusion
In our study, we noted that AMFB was the most common among the three mesenchymal tumors of the lower FGT. In contrast, AAM had the highest recurrence rate, and recurrence was significantly associated with tumor size. Histological findings, especially the type of stromal cells and background vasculature, are of utmost importance for the correct recognition of these tumors, while the role of IHC studies is limited.

How to cite this article
Haroon S, Irshad L, Zia S, et al. (September 17, 2022) Aggressive Angiomyxoma, Angiomyofibroblastoma, and Cellular Angiofibroma of the Lower Female Genital Tract: Related Entities With Different Outcomes. Cureus 14(9):e29250. DOI 10.7759/cureus.29250

Categories: Obstetrics/Gynecology, Pathology, General Surgery
Keywords: mesenchymal tumors of lower female genital tract, female genital tract tumors, cellular angiofibroma,
Introduction
Mesenchymal tumors of the lower female genital tract (FGT), especially involving the vulva, are a miscellaneous group of tumors that include aggressive angiomyxoma (AAM), angiomyofibroblastoma (AMFB), cellular angiofibroma (CAF) and related entities. Histologically, these tumors are composed of spindle to epithelioid stromal cells admixed with vessels, with subtle histological differences. An accurate diagnosis of these tumors is important owing to the differences in the outcome and management. AAMs are relatively aggressive mesenchymal lesions unique to the lower FGT, pelvis and perineum characterized grossly by large size (mostly >10cm) and ill-circumscribed borders. Microscopically, they are composed of spindle cells embedded in hypocellular myxoid stroma, and thick-walled blood vessels [1,2]. AMFBs are related to AAM, however, they are clinically indolent and grossly circumscribed. Microscopically, they show alternating hypo and hypercellularity, and are composed of spindle to epithelioid lesional cells.

Characteristic thick-walled muscular vessels are seldom seen in AMFB, as opposed to AAM [3,4]. Similar to AMFB, CAFs are benign tumors of the vulvovaginal region with a very low recurrence rate. Histologically, they show spindle cells with collagenized to hyalinized stroma and hyalinized medium-size blood vessels [5,6]. Other rare mesenchymal tumors of this region include leiomyomas, superficial angiomysxomas, fibroepithelial polyps, and low-grade fibromyxoid sarcomas. The relative frequency of these tumors in our population is unknown. In this study, we determined the clinicopathological characteristics of these tumors in our population.

Materials And Methods
This is a retrospective cross-sectional study conducted at the Department of Histopathology, Aga Khan University, from January 2005 to December 2019 over a period of 15 years. Cases that were diagnosed as AAM, AMFB, and CAF were selected for inclusion in the study. Cases of lower FGT tumors other than AAM, AMFB, and CAF, like fibroepithelial polyps and superficial angiomyxomas, were excluded from the study. Clinical data, including age and location of the lesion, were obtained from histopathology referral forms. Tissue blocks of all cases were retrieved. Follow-up data were obtained from the patient files, and information regarding disease recurrence was recorded. Cases with missing tissue blocks or clinical/follow-up data were excluded from the study. A total of 207 cases met the inclusion/exclusion criteria and were thus included in the study.

All specimens were resection specimens of lower FGT tumors. Tru-cut and incisional biopsies were excluded from the study. The resected specimens were received by the histopathology laboratory in 10% buffered formalin. After formalin fixation, grossing of the specimens was done according to standard protocols. Tumor size was recorded and sections from resection margins were submitted. Additionally, one representative section per centimeter of the maximum tumor dimension was submitted, followed by routine tissue processing. Cases with incompletely resected tumors (tumors with positive margins) were excluded from the study.

One histological section from each tissue block was stained with hematoxylin and eosin stain, and histopathological findings, including the type of lesional cells (spindled vs. epithelioid), stromal characteristics (myxoid, collagenized, or hyalinized), and background vessels (thick-walled muscular vessels, collagenized vessels) were recorded. Additionally, immunohistochemical (IHC) studies, including vimentin, smooth muscle actin (SMA), and desmin were conducted on representative tissue blocks. Final histopathological diagnoses were rendered considering clinical, histopathological, and IHC findings.

Data analysis was performed using SPSS Statistics v. 26.0 (IBM Corp., Armonk, NY, USA). Chi-square, Fisher’s exact, and Kruskal-Wallis H tests were used to verify the association. Survival analysis was done by the Kaplan-Meier method. P-values <0.05 were considered to be significant.

Results
Our study demonstrated that the mesenchymal tumors of the FGT showed a wide age distribution with the peak incidence between the age of 31-45 years in 42% of cases, followed by patients of <30 years of age (38.6%), with the median age of 33 years. Grossly, the median tumor size in our study was 5 cm. In 47.3% of cases, the tumor size was <5 cm, whereas in only 15% of cases the tumors were more than 10 cm. It was noted that tumors showed a marked predilection for the vulva in 47.3%, followed by the vagina (27.5%) and labia majora (25.1%).

The histological findings in our study showed that the lesional cells were spindle in 58.5% cases and epithelioid in 52.5% cases, surrounded by collagenized stroma in 63.3% cases, myxoid in 41.1%, and hyalinized in 31.9% cases; the vasculature being composed of hyalinized vessels in 50.7% cases and thickened muscular vessels in 41.5% of the cases. Well-defined borders were present in 57.5% of cases.

The relative frequency of these tumors in our population is unknown. In this study, we determined the clinicopathological characteristics of these tumors in our population.

AMFB, CAFs are benign tumors of the vulvovaginal region with a very low recurrence rate. Histologically, they show spindle cells with collagenized to hyalinized stroma and hyalinized medium-size blood vessels [5,6]. Other rare mesenchymal tumors of this region include leiomyomas, superficial angiomysxomas, fibroepithelial polyps, and low-grade fibromyxoid sarcomas. The relative frequency of these tumors in our population is unknown. In this study, we determined the clinicopathological characteristics of these tumors in our population.
| Clinicopathological features | Values |
|-----------------------------|--------|
| Age (years)                 | Median (IQR) 33.0 (15) |
| Age groups                  |        |
| ≤30 years, n (%)            | 80 (38.6) |
| 31-45 years, n (%)          | 87 (42)  |
| >45 years, n (%)            | 40 (19.3) |
| Tumor size (cm)             | Median (IQR) 5.0 (4.0) |
| Tumor size groups           |        |
| <5 cm, n (%)                | 98 (47.3) |
| 6-10 cm, n (%)              | 78 (37.7) |
| >10 cm, n (%)               | 31 (15)  |
| Follow-up duration (years), median (IQR) | 8.0 (5.0) |
| Tumor Site                  |        |
| Labia majora, n (%)         | 52 (25.1) |
| Vagina, n (%)               | 57 (27.5) |
| Vulva, n (%)                | 98 (47.3) |
| Histological findings       |        |
| Lesional cells              |        |
| Spindle                     |        |
| Yes, n (%)                  | 121 (58.5) |
| No, n (%)                   | 86 (41.5) |
| Epithelioid                 |        |
| Yes, n (%)                  | 108 (52.2) |
| No, n (%)                   | 99 (47.8) |
| Stroma                      |        |
| Myxoid stroma               |        |
| Yes, n (%)                  | 85 (41.1) |
| No, n (%)                   | 122 (58.9) |
| Collagenized stroma         |        |
| Yes, n (%)                  | 131 (63.3) |
| No, n (%)                   | 76 (36.7) |
| Hyalinized stroma           |        |
| Yes, n (%)                  | 68 (31.9) |
| No, n (%)                   | 141 (68.1) |
| Stromal smooth muscles      |        |
| Yes, n (%)                  | 46 (22.2) |
| No, n (%)                   | 161 (77.8) |
Vasculation

| Thickened muscular vessels* |  |
|-----------------------------|--|
| Yes, n (%)                  | 86 (41.5) |
| No, n (%)                   | 121 (58.5) |

Hyalinized vessels

| Yes, n (%) | 105 (50.7) |
| No, n (%)  | 102 (49.3) |

Borders

| Ill defined, n (%) | 88 (42.5) |
| Well defined, n (%)| 119 (57.5) |

Immunohistochemical findings

| Smooth muscle actin |  |
|---------------------|--|
| Positive, n (%)     | 112 (54.1) |
| Negative, n (%)     | 95 (45.9) |

| Vimentin |  |
|----------|--|
| Positive, n (%) | 191 (92.3) |
| Negative, n (%) | 16 (7.7) |

| Desmin |  |
|--------|--|
| Positive, n (%) | 58 (28) |
| Negative, n (%) | 149 (72) |

Diagnosis

| Aggressive angiomyxoma, n (%) | 77 (37.2) |
| Angiomyofibroblastoma, n (%)  | 111 (53.6) |
| Cellular angiofibroma, n (%)  | 19 (9.2) |

Recurrence

| Yes, n (%) | 30 (14.5) |
| No, n (%)  | 177 (85.5) |

### TABLE 1: Clinicopathological features of the population under study

IQR: Interquartile range

Table 2 demonstrates the association of the tumors with clinicopathological findings. AAM showed a predilection for patients between the ages of 31-45 years, whereas AMFBs and CAFs were most common in younger age groups of less than 50 years. In 46.8% of cases, the tumor size of AAM was between 6 and 10 cm, while in all cases of CAF (100%) and in most cases of AMFB (53.2%) the tumor size was <5 cm. In our study, all three tumors, AAM (54.5%), AMFB (34.2%), and CAF (94.7%) showed a predilection for the vulva; however, CAF was infrequently seen at the other two sites (vagina and labia majora). Histologically, in all cases of AAM, the lesional cells were spindle (100%), whereas, in 13% of cases epitheloid cells were observed, with myxoid stroma in 92.2% cases, the presence of stromal smooth muscle was noted in 42.9% cases. In 79.2% of cases, the vessels were thick-walled, with 54.5% having hyalinized vessels, and most of the cases (77.9%) had ill-defined borders. Among IHC findings, AMFB was most frequently positive for actin (62.2%), while AAM and AMFB showed more frequent staining for desmin compared to CAF. A significantly higher recurrence rate was observed in AAM (27.3%), compared with AMFB and CAF. Histologically, AMFBs were predominantly composed of epitheloid cells (85.6%), surrounded by collagenized stroma in most cases (80.2%). Around 89.2% of cases of AMFBs had well-defined borders with a recurrence rate of 7.2%. Immunohistochemically, these tumors stained positive for vimentin in most cases (92.8%),
while SMA staining was seen in 62.2% of cases. Histological findings of CAF showed that the lesional cells were spindle with hyalinized stroma in most cases (84.2%). The IHC findings showed that CAFs stained positive for vimentin in 84.2% of the cases. The recurrence rate of CAFs in our study was found to be the least at only 5.3%.

| Clinicopathological features | Diagnosis                                      | p-value  |
|-----------------------------|-----------------------------------------------|----------|
|                             | Aggressive angiomyxoma | Angiomyofibroblastoma | Cellular angiofibroma |
| Age (years)                 | 42.0 (13.5)                     | 32.0 (13.0)                     | 28.0 (13.0)                     | 0.001***                |
| Age groups**                |                                |                                |                                |                         |
| ≤30 years, n (%)           | 18 (23.4)                      | 49 (44.1)                      | 13 (68.4)                      |                         |
| 31-45 years, n (%)         | 40 (51.9)                      | 43 (38.7)                      | 4 (21.1)                       | 0.003***                |
| >45 years, n (%)           | 19 (24.7)                      | 19 (17.1)                      | 2 (10.5)                       |                         |
| Tumor size (cm)            |                                |                                |                                |                         |
| Median (IQR)*              | 7.0 (7.00)                     | 4.0 (3.00)                     | 2.0 (1.7)                      | <0.001***               |
| Tumor size groups**        |                                |                                |                                |                         |
| <5 cm, n (%)               | 20 (26)                        | 59 (53.2)                      | 19 (100)                       |                         |
| 6-10 cm, n (%)             | 36 (46.8)                      | 42 (37.8)                      | 0 (0)                          | <0.001***               |
| >10 cm, n (%)              | 21 (27.3)                      | 10 (9)                         | 0 (0)                          |                         |
| Follow-up duration (years), median (IQR)* | 8.0 (4.0)                     | 7.0 (6.0)                      | 8.0 (5.0)                      | 0.193                  |
| Tumor Site**               |                                |                                |                                |                         |
| Labia majora, n (%)        | 16 (20.8)                      | 36 (32.4)                      | 0 (0)                          |                         |
| Vagina, n (%)              | 19 (24.7)                      | 37 (33.3)                      | 1 (5.3)                        | <0.001***               |
| Vulva, n (%)               | 42 (54.5)                      | 38 (34.2)                      | 18 (94.7)                      |                         |
| Histological findings      |                                |                                |                                |                         |
| Lesional cells             |                                |                                |                                |                         |
| Spindle**                  |                                |                                |                                |                         |
| Yes, n (%)                 | 77 (100)                       | 25 (22.5)                      | 19 (100)                       | <0.001***               |
| No, n (%)                  | 0 (0)                          | 86 (77.5)                      | 0 (0)                          |                         |
| Epithelioid**              |                                |                                |                                |                         |
| Yes, n (%)                 | 10 (13)                        | 95 (85.6)                      | 3 (15.8)                       | <0.001***               |
| No, n (%)                  | 67 (87)                        | 16 (14.4)                      | 16 (84.2)                      |                         |
| Stroma                     |                                |                                |                                |                         |
| Myxoid stroma**            |                                |                                |                                |                         |
| Yes, n (%)                 | 71 (92.2)                      | 12 (10.8)                      | 2 (10.5)                       | <0.001***               |
| No, n (%)                  | 6 (7.8)                        | 99 (89.2)                      | 17 (89.5)                      |                         |
| Collagenized stroma**      |                                |                                |                                |                         |
| Yes, n (%)                 | 31 (40.3)                      | 89 (80.2)                      | 11 (57.9)                      | <0.001***               |
| No, n (%)                  | 46 (59.7)                      | 22 (19.8)                      | 8 (42.1)                       |                         |
| Hyalinized stroma**        |                                |                                |                                |                         |
| Yes, n (%)                 | 17 (22.1)                      | 33 (29.7)                      | 16 (84.2)                      | <0.001***               |
|                              | Yes, n (%) | No, n (%) | p-value |
|------------------------------|------------|-----------|---------|
| Stromal smooth muscles**     | 33 (42.9)  | 44 (57.1) | <0.001*** |
| Vascular                     |            |           |         |
| Thickened muscular vessels** | 61 (79.2)  | 16 (20.8) | <0.001*** |
| Hyalinized vessels**         | 42 (54.5)  | 35 (45.5) | 0.011*** |
| Borders**                    |            |           |         |
| Ill-defined, n (%)           | 60 (77.9)  | 17 (22.1) | <0.001*** |
| Well defined, n (%)          | 12 (10.8)  | 99 (89.2) |         |
| Immunochemical findings      |            |           |         |
| Smooth muscle actin**        | 34 (44.2)  | 43 (55.8) | 0.042*** |
| Vimentin**                   | 72 (93.5)  | 5 (6.5)   | 0.360   |
| Desmin**                     | 19 (24.7)  | 38 (43.2) | 0.024*** |
| Recurrence**                 | 21 (27.3)  | 56 (72.7) | <0.001*** |

**TABLE 2: Association of clinicopathological features with the diagnosis**

*Kruskal-Wallis H test was applied, **Fisher exact/Chi-square test was applied, ***Significant as < 0.05

Table 3 shows the association of recurrence with clinicopathological characteristics. A significant association of recurrence was seen with tumor size. It was noted that the recurrence rate was directly proportional to the size of the tumor and was highest (60%) with a tumor size of more than 10 cm.
| Clinico-pathological features | Recurrence |   | p-value |
|------------------------------|------------|---|----------|
|                              | Yes        | No |          |
| Age (years)                  |            |   |          |
| Median (IQR)*                | 42.0 (17.25)| 32.0 (14.50)| 0.015*** |
| Age groups**                 |            |   |          |
| ≤30 years, n (%)             | 6 (20)     | 74 (41.8) |          |
| 31-45 years, n (%)           | 15 (50)    | 72 (40.7) | 0.056    |
| >45 years, n (%)             | 9 (30)     | 31 (17.5) |          |
| Tumor size (cm)              |            |   |          |
| Median (IQR)*                | 13.0 (9.50)| 4.0 (4.0)  | 0.184    |
| Tumor size groups**          |            |   |          |
| <5 cm, n (%)                 | 3 (10)     | 95 (53.7) |          |
| 6-10 cm, n (%)               | 9 (30)     | 69 (39)   | <0.001***|
| >10 cm, n (%)                | 18 (60)    | 13 (7.3)  |          |
| Follow-up duration (years), median (IQR)* | 8.5 (5.0) | 8.0 (6.0) | 0.195    |
| Tumor site**                 |            |   |          |
| Labia majora, n (%)          | 7 (23.3)   | 45 (25.4) |          |
| Vagina, n (%)                | 9 (30)     | 48 (27.1) | 0.939    |
| Vulva, n (%)                 | 14 (46.7)  | 84 (47.5) |          |
| Smooth muscle actin**        |            |   |          |
| Positive, n (%)              | 14 (46.7)  | 98 (55.4) | 0.377    |
| Negative, n (%)              | 16 (53.3)  | 79 (44.6) |          |
| Vimentin**                   |            |   |          |
| Positive, n (%)              | 28 (93.3)  | 163 (92.1)| 1.0      |
| Negative, n (%)              | 2 (6.7)    | 14 (7.9)  |          |
| Desmin**                     |            |   |          |
| Positive, n (%)              | 7 (23.3)   | 51 (28.8) | 0.537    |
| Negative, n (%)              | 23 (76.7)  | 126 (71.2)|          |

**TABLE 3: Association of clinicopathological features with recurrence**

IQR: Interquartile range

*Kruskal-Wallis H test was applied, **Fisher exact/Chi-square test was applied, ***Significant as < 0.05

Figure 1 shows survival analysis by the Kaplan-Meier method. Recurrence was found to be significantly high in AAM, compared to AMFB and CAF (p=0.002).
Discussion

Vulvo-vaginal mesenchymal neoplasms that are composed of spindle cells, most commonly arising in the vulvovaginal region, often pose diagnostic difficulties for pathologists due to their overlapping histological features [7]. We conducted a study on the three most common mesenchymal tumors of FGT, namely, AAM, AMFB, and CAF. We found that these tumors mostly involve patients between the ages of 31 and 45 years, with the vulva being the most common site, and most of the tumors were found to be of <5 cm in size. AMFB was the most frequent diagnosis, and AAM had the highest frequency of recurrence. Tumor size was significantly found to associate with the recurrence rate. The role of IHC findings was limited in the diagnosis of these tumors and histological characteristics were more diagnostic.

Aggressive angiomyxoma

AAM is a rare mesenchymal tumor of vulvo-vagina that is slow-growing with a high rate of local recurrence but a low metastatic rate [8]. It is a benign tumor that is locally aggressive [9].

We studied the histological and IHC features of these tumors and found that AAMs were all composed of spindle cells (100%) with epithelioid cells present in 13% of cases as well as embedded in a myxoid stroma in most cases; in a few cases stromal smooth muscle presence was noted. A prominent vascular component is a hallmark of this tumor type, including thickened muscular walls in 79.2% of cases and hyalinized vessels in 54.5% of cases. The IHC findings revealed that AAMs stained positive for vimentin in 93.5% of cases, SMA (44.2%), and less commonly for desmin (24.7%). In our study, we found AAM had the highest recurrence rate (27.3%). AAM showed a predilection for patients between the ages of 31 and 45 years. In 46.8% of cases, the tumor size of AAM was between 6 and 10 cm and most commonly affected the vulva, followed by the vagina. Fetsch et al. conducted a study on 29 female patients with AAM; similarly to our study they concluded that the peak incidence of AAM among their patients was in the fourth decade of life with the pelvis, perineum, and vulva being commonly affected sites with most of the tumors being 10 cm or more in size; histologically they found that the neoplastic cells were spindle to stellate having collagenized matrix with blood vessels of variable caliber, with few cells showing smooth muscle differentiation. Immunohistochemically, the neoplastic cells stained positive for desmin, SMA, and vimentin. They found AAM to have a high rate of local recurrence [10].

Chen et al. evaluated the clinicopathological features of AAM in five cases having a median age of 42 years, and most cases affected the pelvis (3/5), whereas one each involved the vulva and buttoc. The average size of these tumors was 18 cm and had ill-defined borders. Morphologically, they found that the lesional cells
were spindle and stellate with myxedematous stroma containing vessels that were unevenly thickened and randomly arranged in the matrix. The IHC studies showed that the tumor cells were mostly positive for vimentin, desmin, estrogen receptors (ER) and progesterone receptors (PR), while weak expression of SMA was also noticed. They found that AAM had a high local recurrence range between 25 and 47% [11]. Due to the locally aggressive nature of AAM, these tumors should be managed appropriately and long-term follow-up of the patients should be done [12].

Angiomyofibroblastoma

AMFB is a rare, slow-growing mesenchymal tumor, with a predilection for FGT with a low tendency to reoccur. The majority of these tumors are small, measuring <5 cm [13]. The average age of occurrence of AFMB is 45.8 years [14]. In our study, we found that AMFBs had a predilection for the younger age group of <30 years of age, most commonly arising in the vulva, with a tumor size of <5 cm; these tumors were mostly composed of epithelioid cells in 85.6% of cases, with background collagenized stroma in 80.2%, though a few cases showed a variation of myoid and hyalinized stroma. These neoplasms showed a prominent vascular component including hyalinized vessels. The IHC findings revealed that the stromal cells expressed immunoreactivity for vimentin in 92.8% of cases, whereas 34.2% of cases stained positively for desmin.

Magro et al. assessed the morphological and IHC features of 11 cases of vulvo-vaginal AMFB and concluded that the common histological features among the cases were the presence of spindle to epithelioid lesional cells embedded in an edematous to fibrous stroma having thin-walled vessels. All these tumors stained positive for vimentin, whereas in a few cases, tumor cells were positive for desmin and SMA [4]. Seo et al. reported a case of AMFB of the vulva, similar to our study; they found that the tumor cells expressed positive for vimentin and had estrogen/progesterone receptor expression [15].

Cellular angiofibroma

CAF is a rare benign mesenchymal tumor, which is fibroblastic, usually arising in the vulvovaginal area of middle-aged women, these tumors are small, usually <5 cm [16]. Typically, CAF is composed of spindle shape cells embedded in a stroma containing wispy collagen having medium-sized hyalinized vessels [17].

According to our study, CAF mostly occurred in the younger age group (<30cm), and the size of the tumor in most cases was <5 cm, showing a predilection for the vulvovaginal region, we found that the microscopic findings of CAF included spindle-shaped cells with intermixed epithelioid cells in a few cases, embedded in a hyalinized stroma in most cases (84.2%), whereas, in 57.9% of cases there was overlapping collagenized stroma, and the vascular component consisted of hyalinized blood vessels. Immunohistochemically, these tumors were positive for vimentin (84.2%) in most cases, followed by actin in 47.4% of cases.

Colombat et al. presented a case report of vulvar CAF in a 37-year-old female and found that morphologically the tumor cells were composed of spindle cells, with numerous thick and thin-walled blood vessels which were mostly hyalinized and the stromal cells showed immunoreactivity to vimentin [18]. Angelico et al. did an overview of vulvo-vaginal stromal tumors and concluded that CAF is composed of spindle cells with a predominant fibrous stroma, containing numerous hyalinized small-medium blood vessels [19]. Iwasa et al. studied the clinicopathological and IHC study of CAF in 51 cases and similar to our study, they found that the most common site of CAF among females was the vulvovaginal region. Microscopic studies of the tumor showed that these neoplasms were composed of spindle cells with an edematous to fibrous background stroma around small to medium-sized hyalinized vessels. Moreover, they found that most of the tumors (60%) expressed positively for CD54 [5].

Our study can be viewed with a few limitations, the most important of which is the lack of molecular analysis of these tumors. Therefore, we suggest that a detailed molecular analysis of these tumors should be carried out and new biomarkers should be sought that predict recurrence in these tumors.

Conclusions

In this study, we found that AMFB is the most common mesenchymal tumor of the lower FGT, whereas AAM was more frequently associated with recurrence. We also noted that size is the most important factor in predicting recurrence in these tumors. Moreover, histological features of the background stroma and vasculature are pivotal in the exact characterization of these tumors, while the role of IHC studies is still limited. More studies are needed to identify prognostic biomarkers in these tumors, especially AAM, and to uncover the molecular features of these tumors.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Steeper TA, Rosai J: Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol. 1983, 7:463-75. 10.1097/00000478-198307000-00009

2. Bégin L, Clement PB, Kirk ME, Jothy S, Maughan WT, Ferenczy A: Aggressive angiomyxoma of pelvic soft parts: a clinicopathologic study of nine cases. Hum Pathol. 1985, 16:621-8. 10.1016/0196-8177(85)90112-x

3. Fletcher CD, Tsang WY, Fisher C, Lee KC, Chan JK: Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Pathol. 1992, 16:375-82. 10.1097/00000478-199204000-00006

4. Magro G, Righi A, Caltabiano R, Casorzo L, Michel M: Vulvovaginal angiomyofibroblastomas: morphologic, immunohistochemical, and fluorescence in situ hybridization analysis for deletion of 13q14 region. Hum Pathol. 2014, 45:1647-55. 10.1016/j.humpath.2014.05.020

5. Iwasa Y, Fletcher CD: Cellular angiofibroma: clinicopathologic and immunohistochemical analysis of 51 cases. Am J Surg Pathol. 2004, 28:1426-35. 10.1097/01.pas.0000138002.46650.95

6. McCluggage WG, Ganesan R, Hirschowitz L, Rollason TP: Cellular angiofibroma and related fibromatoses lesions of the vulva: report of a series of cases with a morphological spectrum wider than previously described. Histopathology. 2004, 45:560-8. 10.1111/j.1365-2559.2004.01923.x

7. McCluggage WG: A review and update of morphologically bland vulvovaginal mesenchymal lesions. Int J Gynecol Pathol. 2005, 24:26-38.

8. Kura MM, Jindal SR, Khemani UN: Aggressive angiomyxoma of the vulva: an uncommon entity. Indian Dermatol Online J. 2012, 3:128-30. 10.4103/2229-5178.96712

9. Kelley SR: Robotic extralevator excision of a retrorectal giant aggressive angiomyxoma. Obstet Gynecol Sci. 2018, 61:693-7. 10.5468/ogs.2018.61.6.693

10. Fetsch JF, Laskin WB, Lefkowitz M, Kindblom LG, Meis-Kindblom JM: Aggressive angiomyxoma: a clinicopathologic study of 29 female patients. Cancer. 1996, 78:79-90. 10.1002/(SICI)1097-0424(19960701)78:1<79::AID-CNCR13>3.0.CO;2-4

11. Chen H, Zhao H, Xie Y, Jin M: Clinicopathological features and differential diagnosis of aggressive angiomyxoma of the female pelvis: 5 case reports and literature review. Medicine (Baltimore). 2017, 96:6820. 10.1097/MD.0000000000006820

12. Amin A, El Badawy S, Bull A: Aggressive angiomyxoma of the vulva. J Obstet Gynaecol. 2013, 33:325-6. 10.3109/01443615.2012.751456

13. Park BH, Shin MK, Lee M, Park SK, Park S, Kim H: Angiomyofibroblastoma of the vulva: a case report with literature review. Case Rep Clin Med. 2013, 2:221-4. 10.4236/crcm.2013.23060

14. Nielsen GP, Young RH: Mesenchymal tumors and tumor-like lesions of the female genital tract: a selective review with emphasis on recently described entities. Int J Gynecol Pathol. 2001, 20:105-27. 10.1097/00004347-200104000-00002

15. Seo JW, Lee KA, Yoon NR, Lee JW, Kim BG, Bae DS: Angiomyofibroblastoma of the vulva. Obstet Gynecol Sci. 2013, 56:349-51. 10.5448/ogs.2013.56.5.349

16. Nucci MR, Graeter SR, Fletcher CD: Cellular angiofibroma: a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma. Am J Surg Pathol. 1997, 21:636-44. 10.1097/00000478-199706000-00002

17. Schoonmeester JK, Fritchie KJ: Genital soft tissue tumors. J Cutan Pathol. 2015, 42:441-51. 10.1111/cup.12507

18. Colombat M, Liard-Meillon ME, De Saint-Maur P, Sevestre H, Gontier MF: Cellular angiofibroma. A rare vulvar tumor. Report of a case. Ann Pathol. 2001, 21:145-8.

19. Angelico G, Marletta S, Broggi G, Vigneri P, Vecchio GM, Salvatorelli L, Magro G: Practical approach to the diagnosis of the vulvo-vaginal stromal tumors: an overview. Diagnostics (Basel). 2022, 12:357. 10.3390/diagnostics12020357